NEW YORK (GenomeWeb News) – Interleukin Genetics has filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.

The firm said in its SEC registration that it may offer shares of common stock and preferred stock, debt securities, warrants, or rights or contracts for any of those securities, either individually or in units.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.